Tislelizumab,Sorafenib
BeiGene,Novartis,Bayer
[]
tislelizumab noninferior to sorafenib for advanced hcc. another option for patients who are not a candidate for doublet therapy. we were fortunate to enroll patietnts as one of the only us sites to contribute to this study. #hcc #gi23 
Daughter, sister, wife, medical oncologist  caring for patients with GI cancers, she/her. Views are my own. Have a blessed day! @UTHealthSAMDA #GIcancers